Icsori

Fluticasone propionate, the active ingredient in Icsori, is an inhaled corticosteroid presented as an inhalation formulation for inhalation use. It treats asthma and chronic obstructive pulmonary disease in adults and children. GNH USA supplies Icsori as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluticasone propionate is an inhaled corticosteroid used in respiratory disease management.

Asthma: improves control of symptoms and reduces the frequency of exacerbations. COPD: decreases airway inflammation and helps lower the risk of flare‑ups. Chronic bronchitis: reduces inflammatory response in the airways, aiding symptom relief.

Fluticasone propionate may cause a range of adverse reactions.

Common Side Effects: - Oral thrush (candidiasis) - Hoarseness or dysphonia - Cough or throat irritation - Headache - Nasal congestion - Dry mouth

Serious or Rare Side Effects: - Adrenal suppression - Pneumonia, especially in COPD patients - Severe allergic reactions (anaphylaxis) - Decreased bone mineral density with long‑term use - Vision changes such as cataracts or glaucoma

When prescribing or using fluticasone propionate, consider the following precautions.

Assess infection risk: monitor for signs of respiratory infections. Monitor growth in children: regular height and weight checks are advised. Use a spacer device: helps reduce oropharyngeal deposition and irritation. Avoid abrupt discontinuation: tapering may be needed after prolonged therapy. Consider bone health: evaluate calcium and vitamin D intake for long‑term users. Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and direct sunlight.

Fluticasone propionate can interact with other medicines; awareness of these interactions helps ensure safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic steroid exposure. - Systemic corticosteroids: additive immunosuppressive effects. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Short‑acting β2‑agonists: may mask worsening asthma symptoms. - Diuretics: potential for hypokalemia when combined with systemic steroids. - Ritonavir: may raise fluticasone plasma levels, requiring clinical monitoring.